227 related articles for article (PubMed ID: 32145111)
21. INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.
Leleu X; Lee HC; Zonder JA; Macro M; Ramasamy K; Hulin C; Silar J; Kuhn M; Ren K; Bent-Ennakhil N; Cherepanov D; Stull DM; Terpos E
Future Oncol; 2024 May; 20(14):935-950. PubMed ID: 38197267
[No Abstract] [Full Text] [Related]
22. Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
Gupta N; Yang H; Hanley MJ; Zhang S; Liu R; Kumar S; Richardson PG; Skacel T; Venkatakrishnan K
Target Oncol; 2017 Oct; 12(5):643-654. PubMed ID: 28803351
[TBL] [Abstract][Full Text] [Related]
23. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Dimopoulos MA; Schjesvold F; Doronin V; Vinogradova O; Quach H; Leleu X; Montes YG; Ramasamy K; Pompa A; Levin MD; Lee C; Mellqvist UH; Fenk R; Demarquette H; Sati H; Vorog A; Labotka R; Du J; Darif M; Kumar S
Blood Cancer J; 2022 Jan; 12(1):9. PubMed ID: 35075109
[TBL] [Abstract][Full Text] [Related]
24. A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma.
Chng WJ; Lonial S; Morgan GJ; Iida S; Moreau P; Kumar SK; Twumasi-Ankrah P; Villarreal M; Dash AB; Vorog A; Zhang X; Suryanarayan K; Labotka R; Dimopoulos MA; Rajkumar SV
Blood Cancer J; 2023 Jan; 13(1):14. PubMed ID: 36631458
[TBL] [Abstract][Full Text] [Related]
25. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Rajkumar SV; Richardson PG
Leukemia; 2019 Jul; 33(7):1736-1746. PubMed ID: 30696949
[TBL] [Abstract][Full Text] [Related]
26. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.
Dimopoulos MA; Lonial S; Betts KA; Chen C; Zichlin ML; Brun A; Signorovitch JE; Makenbaeva D; Mekan S; Sy O; Weisel K; Richardson PG
Cancer; 2018 Oct; 124(20):4032-4043. PubMed ID: 30204239
[TBL] [Abstract][Full Text] [Related]
27. [The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China].
Yang Y; Xia ZJ; Zhang WH; Fu CC; Bao L; Chen B; Ding KY; Wang SL; Luo J; Li BZ; Hua LM; Yang W; Zhou X; Wang L; Xu TH; Wang WD; Wu GL; Huang Y; Li J; Liu P
Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):628-634. PubMed ID: 34547867
[No Abstract] [Full Text] [Related]
28. Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting.
Ludwig H; Ramasamy K; Mateos MV; Kishore B; Gergely V; Ladicka M; Ori A; Simoni L; Bent-Ennakhil N; Stull DM; Gavini F; Terpos E; Hájek R
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):e40-e49.e3. PubMed ID: 37996265
[TBL] [Abstract][Full Text] [Related]
29. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
[TBL] [Abstract][Full Text] [Related]
30. A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan.
Horigome Y; Iino M; Harazaki Y; Kobayashi T; Handa H; Hiramatsu Y; Kuroi T; Tanimoto K; Matsue K; Abe M; Ishida T; Ito S; Iwasaki H; Kuroda J; Shibayama H; Sunami K; Takamatsu H; Tamura H; Hayashi T; Akagi K; Maeda T; Yoshida T; Mori I; Shinozaki T; Iida S
Ann Hematol; 2024 Feb; 103(2):475-488. PubMed ID: 37695378
[TBL] [Abstract][Full Text] [Related]
31. [Safety and management of adverse events of ixazomib/lenalidomide/dexamethasone therapy in Japanese patients with relapsed/refractory multiple myeloma].
Iida S; Izumi T; Aotsuka N; Komeno T; Ishida T; Sunami K; Handa H; Berg D; Kase Y; Soeda J
Rinsho Ketsueki; 2018; 59(11):2399-2407. PubMed ID: 30531133
[TBL] [Abstract][Full Text] [Related]
32. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
Li J; Bao L; Xia Z; Wang S; Zhou X; Ding K; Zhang W; Yang W; Li B; Fu C; Chen B; Hua L; Wang L; Luo J; Yang Y; Xu T; Wang W; Huang Y; Wu G; Liu P
Ann Hematol; 2020 Nov; 99(11):2589-2598. PubMed ID: 32892275
[TBL] [Abstract][Full Text] [Related]
33. Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma.
Lee JH; Kim SH; Kim HR; Min CK; Lee JJ; Shin HJ; Jo JC; Lee JY; Moon JH; Kim K
Int J Hematol; 2023 Feb; 117(2):225-235. PubMed ID: 36369635
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy and Safety of Ixazomib-Lenalidomide-Dexamethasone Therapy for Relapsed and Refractory Multiple Myeloma].
Takakuwa T; Araki T; Miura A; Fujitani Y; Takeoka Y; Ohta K; Yamamura R
Gan To Kagaku Ryoho; 2019 Jun; 46(6):1043-1047. PubMed ID: 31273172
[TBL] [Abstract][Full Text] [Related]
35. ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone.
Kogure Y; Handa H; Ito Y; Ri M; Horigome Y; Iino M; Harazaki Y; Kobayashi T; Abe M; Ishida T; Ito S; Iwasaki H; Kuroda J; Shibayama H; Sunami K; Takamatsu H; Tamura H; Hayashi T; Akagi K; Shinozaki T; Yoshida T; Mori I; Iida S; Maeda T; Kataoka K
Blood; 2024 Jun; 143(23):2401-2413. PubMed ID: 38427753
[TBL] [Abstract][Full Text] [Related]
36. Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.
Al-Salama ZT; Garnock-Jones KP; Scott LJ
Target Oncol; 2017 Aug; 12(4):535-542. PubMed ID: 28660423
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma - case series and literature review.
Szudy-Szczyrek A; Chocholska S; Bachanek-Mitura O; Czabak O; Mlak R; Szczyrek M; Muzyka-Kasietczuk J; Hus M
Ann Agric Environ Med; 2022 Mar; 29(1):103-109. PubMed ID: 35352912
[TBL] [Abstract][Full Text] [Related]
38. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
39. [Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime].
Hardi A; Varga G; Nagy Z; Kosztolányi S; Váróczy L; Plander M; Schneider T; Demeter J; Alizadeh H; Illés Á; Masszi T; Mikala G
Orv Hetil; 2021 Sep; 162(36):1451-1458. PubMed ID: 34482291
[TBL] [Abstract][Full Text] [Related]
40. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Facon T; Kumar SK; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Wang J; Van Rampelbergh R; Uhlar CM; Tromp B; Delioukina M; Vermeulen J; Usmani SZ
Lancet Oncol; 2021 Nov; 22(11):1582-1596. PubMed ID: 34655533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]